MA47500B1 - Dérivés de pyrrolo[1,2-b]pyridazine - Google Patents
Dérivés de pyrrolo[1,2-b]pyridazineInfo
- Publication number
- MA47500B1 MA47500B1 MA47500A MA47500A MA47500B1 MA 47500 B1 MA47500 B1 MA 47500B1 MA 47500 A MA47500 A MA 47500A MA 47500 A MA47500 A MA 47500A MA 47500 B1 MA47500 B1 MA 47500B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolo
- pyridazine derivatives
- pyridazine
- derivatives
- variables
- Prior art date
Links
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical class C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne un composé de formule (i), dans laquelle les groupes de variables sont définis dans la description.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460013P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018431 WO2018152368A1 (fr) | 2017-02-16 | 2018-02-15 | Dérivés de pyrrolo [1,2-b] pyridazine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47500A MA47500A (fr) | 2019-12-25 |
| MA47500B1 true MA47500B1 (fr) | 2024-02-29 |
Family
ID=61563476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47500A MA47500B1 (fr) | 2017-02-16 | 2018-02-15 | Dérivés de pyrrolo[1,2-b]pyridazine |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10336762B2 (fr) |
| EP (1) | EP3583105B1 (fr) |
| JP (3) | JP6924267B2 (fr) |
| KR (1) | KR102337055B1 (fr) |
| CN (1) | CN110300754A (fr) |
| AR (1) | AR110935A1 (fr) |
| AU (2) | AU2018221812B2 (fr) |
| CA (1) | CA3050148A1 (fr) |
| CL (1) | CL2019002306A1 (fr) |
| CO (1) | CO2019008868A2 (fr) |
| CR (1) | CR20190373A (fr) |
| DK (1) | DK3583105T3 (fr) |
| DO (1) | DOP2019000214A (fr) |
| EA (1) | EA201991544A1 (fr) |
| ES (1) | ES2975767T3 (fr) |
| FI (1) | FI3583105T3 (fr) |
| HU (1) | HUE065978T2 (fr) |
| IL (1) | IL267979B (fr) |
| JO (1) | JOP20180011A1 (fr) |
| LT (1) | LT3583105T (fr) |
| MA (1) | MA47500B1 (fr) |
| MX (2) | MX2019009840A (fr) |
| PE (1) | PE20191540A1 (fr) |
| PH (1) | PH12019550128A1 (fr) |
| PL (1) | PL3583105T3 (fr) |
| PT (1) | PT3583105T (fr) |
| RS (1) | RS65397B1 (fr) |
| SA (1) | SA519402462B1 (fr) |
| SG (1) | SG11201906763RA (fr) |
| SI (1) | SI3583105T1 (fr) |
| SM (1) | SMT202400146T1 (fr) |
| TW (3) | TW202340194A (fr) |
| UA (1) | UA124548C2 (fr) |
| UY (1) | UY37608A (fr) |
| WO (1) | WO2018152368A1 (fr) |
| ZA (1) | ZA201905456B (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060693A1 (fr) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019111218A1 (fr) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (fr) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
| WO2019140387A1 (fr) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
| WO2020010227A1 (fr) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et leurs utilisations |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| AU2019301510B2 (en) | 2018-07-09 | 2024-06-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anthelminthic heterocyclic compounds |
| TWI842978B (zh) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| CN112566697B (zh) * | 2018-08-13 | 2024-04-16 | 吉利德科学公司 | 作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物 |
| WO2020036830A1 (fr) * | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Dérivés de pyrrolo [1,2-b] pyridazine en tant qu'inhibiteurs d'irak4 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CA3133100A1 (fr) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Composes d'aza-benzothiophene et d'aza-benzofurane anthelminthiques |
| CN111821308B (zh) * | 2019-04-15 | 2021-10-08 | 中国科学院上海药物研究所 | 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (fr) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| CN110755452B (zh) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | 干细胞治疗骨关节炎的用途 |
| CN110755451B (zh) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | 用于治疗骨关节炎的间充质干细胞组合物及其用途 |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127283A2 (fr) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| WO2021127190A1 (fr) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| EP4107158A1 (fr) | 2020-02-19 | 2022-12-28 | Nurix Therapeutics, Inc. | Agents de dégradation bifonctionnels de kinases associées au récepteur de l'interleukine-1 et leur utilisation thérapeutique |
| KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (fr) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak4 et leurs utilisations |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| UY39995A (es) | 2021-11-01 | 2023-05-15 | Boehringer Ingelheim Vetmedica GmbH | Compuestos de pirrolopiridazina como antihelmínticos |
| EP4472967A4 (fr) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Agents de dégradation d'irak et leurs utilisations |
| AR129535A1 (es) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | Derivados de carboxamida heterocíclicos bicíclicos microbiocidas |
| WO2024089191A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Dérivés de dihydrooxadiazine hétérobicycliques microbiocides |
| US20250042906A1 (en) * | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Processes for making irak4 inhibitors |
| CN117849327A (zh) * | 2024-03-06 | 2024-04-09 | 军科正源（北京）药物研究有限责任公司 | 用于检测苏金单抗抗药性抗体的方法 |
| WO2026019979A1 (fr) * | 2024-07-19 | 2026-01-22 | Merck Sharp & Dohme Llc | Inhibiteurs de la tyrosine kinase vegfr de type pyrrolopyridazine |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| WO2008016643A2 (fr) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Entités chimiques, compositions et méthodes |
| KR20090049076A (ko) | 2006-09-07 | 2009-05-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체 |
| DE102009033208A1 (de) | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| KR20180099933A (ko) | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | 복소환 아민 및 이의 용도 |
| BR112013015460B1 (pt) | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| WO2012129258A1 (fr) | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole |
| WO2013042137A1 (fr) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4 |
| WO2013066729A1 (fr) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine |
| RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
| CN104582705A (zh) | 2012-01-10 | 2015-04-29 | 林伯士艾瑞斯公司 | 白介素-1受体相关激酶(irak)抑制剂和其用途 |
| CN104254533B (zh) | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| WO2013106614A1 (fr) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Composés pyridyles à substitution triazolyle utiles comme inhibiteurs de kinases |
| EP2802576B1 (fr) | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Composés pyridiniques à substitution hétérocyclique utiles en tant qu'inhibiteurs de kinases |
| SG11201500005SA (en) | 2012-07-10 | 2015-01-29 | Ares Trading Sa | Pyrimidine pyrazolyl derivatives |
| WO2014011906A2 (fr) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014058685A1 (fr) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité de l'irak4 |
| WO2014058691A1 (fr) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibiteurs d'activité d'irak4 |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| SG11201503395TA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
| RU2015118647A (ru) | 2012-11-20 | 2017-01-10 | Дженентек, Инк. | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr |
| JP2016505012A (ja) | 2013-01-10 | 2016-02-18 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| LT2953952T (lt) | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Makrocikliniai piridazinono dariniai |
| EP2953944B1 (fr) | 2013-02-07 | 2017-04-26 | Merck Patent GmbH | Dérivés de pyridazinone-amides |
| EP2970334B1 (fr) | 2013-03-15 | 2018-05-23 | Biogen MA Inc. | Composés macrocycliques comme inhibiteurs d'irak4 pour le traitement de maladies inflammatoires |
| WO2014210354A1 (fr) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Composés d'azaindazole en tant qu'inhibiteurs de la t790m contenant des mutants de l'egfr |
| EP3019171B1 (fr) | 2013-07-11 | 2018-09-05 | Merck Sharp & Dohme Corp. | Inhibiteurs amidopyrazole substitués de kinases associées aux récepteurs de l'interleukine (irak -4) |
| BR112016006319A2 (pt) | 2013-09-27 | 2017-08-01 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| CN105899505B (zh) | 2013-11-08 | 2018-08-28 | 武田药品工业株式会社 | 用于治疗自身免疫病症的吡唑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| TW201609693A (zh) * | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| US10314841B2 (en) | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
| SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| FI3805233T3 (fi) | 2014-01-13 | 2024-04-17 | Aurigene Oncology Ltd | N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon |
| MA39838B1 (fr) | 2014-04-04 | 2019-05-31 | Pfizer | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 |
| JP2017513954A (ja) | 2014-04-22 | 2017-06-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| JP2017518348A (ja) | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| US10246456B2 (en) | 2014-07-18 | 2019-04-02 | Biogen Ma Inc. | IRAK4 inhibiting agents |
| US9926330B2 (en) | 2014-09-30 | 2018-03-27 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9932350B2 (en) | 2014-09-30 | 2018-04-03 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP3200790B1 (fr) | 2014-09-30 | 2020-08-26 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 |
| CA2964982C (fr) | 2014-11-20 | 2022-07-05 | Merck Patent Gmbh | Composes heteroaryles servant d'inhibiteurs d'irak, et leurs utilisations |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| EP3253764B1 (fr) | 2015-02-05 | 2021-06-09 | Merck Patent GmbH | Composés macrocycliques comme inhibiteurs d'irak1/4 et leurs utilisations |
| BR112017014970B1 (pt) | 2015-02-06 | 2022-11-16 | Merck Patent Gmbh | Macrociclos de piridazinona como inibidores de irak, seus usos, e composição farmacêutica |
| US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| WO2016144848A1 (fr) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Inhibiteurs de pyrrolotriazine de l'activité d'irak4 |
| EP3268003B1 (fr) | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thénopyrazines inhibitrices de l'activité de l'irak4 |
| EP3267996B1 (fr) | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine |
| EA039043B1 (ru) | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
| UY36660A (es) | 2015-04-30 | 2016-11-30 | Bayer Pharma AG | Combinaciones de inhibidores de irak4 |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| WO2016210036A1 (fr) * | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Composés aminopyridine substitués par un hétéroaryle |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| WO2017004134A1 (fr) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
| WO2017004133A1 (fr) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Inhibiteurs d'irak et utilisations de ceux-ci |
| JP2018524365A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としての置換アザ化合物 |
| BR112018000624A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| MX384172B (es) | 2015-08-04 | 2025-03-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de pirazol pirimidina y sus usos. |
| JP6994454B2 (ja) | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
| KR102048719B1 (ko) | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
| KR102110573B1 (ko) | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
| CA2995153A1 (fr) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Composes aryle ou heteroaryle condenses bicycliques |
| ES2865199T3 (es) | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
| CN108290879B (zh) | 2015-09-18 | 2022-01-11 | 默克专利有限公司 | 用作irak抑制剂的杂芳基化合物及其用途 |
| KR102650026B1 (ko) | 2015-09-18 | 2024-03-22 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
| GB201518456D0 (en) | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| EP3394066A2 (fr) | 2015-12-22 | 2018-10-31 | H. Hoffnabb-La Roche Ag | Dérivés pyrazolo [1,5 a]pyrimidine en tant que modulateurs d'irak 4 |
| WO2017108744A1 (fr) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Nouveaux indazoles substitués, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour produire des médicaments |
| WO2017127430A1 (fr) | 2016-01-20 | 2017-07-27 | Biogen Ma Inc. | Agents inhibiteurs d'irak4 |
| UA123169C2 (uk) | 2016-04-29 | 2021-02-24 | Байєр Фарма Акцієнгезелльшафт | Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду |
| WO2017205769A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 |
| WO2017205762A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 |
| WO2017205766A1 (fr) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibiteurs de la kinase associée au récepteur de l'interleukine-1 |
| WO2017207385A1 (fr) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | 3-methylindazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments |
| JP7065840B2 (ja) | 2016-06-27 | 2022-05-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法 |
| US10414753B2 (en) | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
| CN109890829B (zh) | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
-
2018
- 2018-02-05 TW TW111148495A patent/TW202340194A/zh unknown
- 2018-02-05 TW TW107103929A patent/TWI733982B/zh active
- 2018-02-05 TW TW110124807A patent/TWI790674B/zh active
- 2018-02-15 AU AU2018221812A patent/AU2018221812B2/en active Active
- 2018-02-15 WO PCT/US2018/018431 patent/WO2018152368A1/fr not_active Ceased
- 2018-02-15 CA CA3050148A patent/CA3050148A1/fr active Pending
- 2018-02-15 MA MA47500A patent/MA47500B1/fr unknown
- 2018-02-15 JO JOP/2018/0011A patent/JOP20180011A1/ar unknown
- 2018-02-15 SG SG11201906763RA patent/SG11201906763RA/en unknown
- 2018-02-15 PT PT187087960T patent/PT3583105T/pt unknown
- 2018-02-15 ES ES18708796T patent/ES2975767T3/es active Active
- 2018-02-15 CN CN201880012452.8A patent/CN110300754A/zh active Pending
- 2018-02-15 HU HUE18708796A patent/HUE065978T2/hu unknown
- 2018-02-15 LT LTEPPCT/US2018/018431T patent/LT3583105T/lt unknown
- 2018-02-15 JP JP2019543909A patent/JP6924267B2/ja active Active
- 2018-02-15 CR CR20190373A patent/CR20190373A/es unknown
- 2018-02-15 UA UAA201908592A patent/UA124548C2/uk unknown
- 2018-02-15 MX MX2019009840A patent/MX2019009840A/es unknown
- 2018-02-15 FI FIEP18708796.0T patent/FI3583105T3/fi active
- 2018-02-15 EP EP18708796.0A patent/EP3583105B1/fr active Active
- 2018-02-15 SI SI201831068T patent/SI3583105T1/sl unknown
- 2018-02-15 PL PL18708796.0T patent/PL3583105T3/pl unknown
- 2018-02-15 RS RS20240424A patent/RS65397B1/sr unknown
- 2018-02-15 DK DK18708796.0T patent/DK3583105T3/da active
- 2018-02-15 EA EA201991544A patent/EA201991544A1/ru unknown
- 2018-02-15 SM SM20240146T patent/SMT202400146T1/it unknown
- 2018-02-15 KR KR1020197026476A patent/KR102337055B1/ko active Active
- 2018-02-15 US US15/898,095 patent/US10336762B2/en active Active
- 2018-02-15 IL IL267979A patent/IL267979B/en unknown
- 2018-02-15 PE PE2019001681A patent/PE20191540A1/es unknown
- 2018-02-16 UY UY0001037608A patent/UY37608A/es not_active Application Discontinuation
- 2018-02-16 AR ARP180100369A patent/AR110935A1/es unknown
-
2019
- 2019-07-11 PH PH12019550128A patent/PH12019550128A1/en unknown
- 2019-08-14 CL CL2019002306A patent/CL2019002306A1/es unknown
- 2019-08-15 CO CONC2019/0008868A patent/CO2019008868A2/es unknown
- 2019-08-15 DO DO2019000214A patent/DOP2019000214A/es unknown
- 2019-08-16 MX MX2023010197A patent/MX2023010197A/es unknown
- 2019-08-18 SA SA519402462A patent/SA519402462B1/ar unknown
- 2019-08-19 ZA ZA2019/05456A patent/ZA201905456B/en unknown
-
2021
- 2021-07-30 JP JP2021125416A patent/JP2021176902A/ja not_active Withdrawn
-
2022
- 2022-09-08 AU AU2022228165A patent/AU2022228165A1/en not_active Abandoned
-
2023
- 2023-04-28 JP JP2023074711A patent/JP2023100791A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47500B1 (fr) | Dérivés de pyrrolo[1,2-b]pyridazine | |
| PH12017502171B1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| MA38432A1 (fr) | Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine | |
| MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
| PH12019500480A1 (en) | Pyridine compound | |
| EA201791011A1 (ru) | 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| EP3380475A4 (fr) | Dérivés d'octahydropyrrolo [3, 4-c | |
| MX377489B (es) | Compuesto de pirazolo[1,5-a]pirimidina. | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| PH12019501171A1 (en) | Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| EA202092858A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА | |
| EA201891769A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ | |
| EP3679042A4 (fr) | Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MX394038B (es) | Derivados de pirrolotriazina como inhibidores de cinasas. | |
| MA53165A (fr) | Dérivés d'imidazo[1,2-b]pyridazine utilisés en tant qu'inhibiteurs de trk | |
| EP3781142A4 (fr) | Nouveaux composés [1.1.1] bicyclo utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor | |
| MX2017003415A (es) | Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace. | |
| NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos |